lars brichta
coo and director of clinical and scientific affairs
chemistry rx
Lars graduated from pharmacy school at the Martin Luther University in Halle, Germany and received his Ph.D. in neurogenetics from the Universities of Bonn and Cologne. Before moving to the United States, he worked in hospital and retail pharmacies in Germany. He also gained experience in the Research and Development department of Novartis Pharma AG in Basel, Switzerland, where he studied the impact of pharmaceutical excipients on the pharmacokinetic behavior of antihypertensive drugs.
Lars is an expert in the field of neurologic and neurodegenerative disorders. After training at the National Institutes of Health, he studied the degeneration of motor neurons in spinal muscular atrophy (SMA), a rare genetic disease that mainly affects children, and discovered the therapeutic potential of histone deacetylase inhibitors. From 2006 until 2015, he carried out research focusing on the molecular underpinnings of dopaminergic neuron degeneration in Parkinson’s disease at the Rockefeller University in New York in the laboratory of Nobel Laureate Paul Greengard and identified novel proteins involved in the loss of these neurons. Lars published a number of articles in several renowned scientific journals.
At Chemistry Rx, Lars provides consultations on novel and specialty medications to practitioners and patients and supports practitioners in obtaining prior authorizations. He specializes in the development of novel formulations for various disorders with a focus on dermatologic conditions in children and adults as well as mitochondrial, metabolic and other rare disorders. One of the recent projects in which Lars has been involved was the development of topical Janus kinase inhibitors for pediatric alopecia.
Learn more about Lars: https://www.linkedin.com/in/lars-brichta-pharmd-phd-9b77bb106/